Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Gene therapy in dogs shows hope for muscular dystrophy
Labrador
In the study, dogs - which have a similar body size to that of a diseased boy - were injected with the disease when they were two to three months old.

Researchers on the cusp of having a treatment for the disease

A team of researchers have successfully treated dogs with muscular dystrophy using gene therapy. The treatment could pave the the way for clinical trials in humans within the next few years.

The study, published in the journal Human Molecular Genetics, demonstrates for the first time that a common virus can deliver the microgene, which protects against the virus, to all muscles in that of diseased dog.

Muscular dystrophy affects around 250,000 people in the USA and occurs when damaged muscle tissue is replaced with fibrous, fatty or bony tissue and loses function.

Patients with the disease have a gene mutation that disrupts the production of a protein known as 'dystrophin". This is one of the largest genes in the human body and its absence can eventually lead to muscle cell degeneration and death.

Study leader Dongsheg Duan from the University of Missouri explains: “Due to its size, it is impossible to deliver the entire gene with a gene therapy vector, which is the vehicle that carries the therapeutic gene to the correct site in the body.

“Through previous research, we were able to develop a miniature version of this gene called a microgene. This minimised dystrophin protected all muscles in the body of diseased mice.”

In the study, dogs - which have a similar body size to that of a diseased boy - were injected with the disease when they were two to three months old and just starting to show signs of muscular dystrophy.  The dogs are now six to seven months old and continue to develop normally.

“The virus we are using is one of the most common viruses; it is also a virus that produces no symptoms in the human body, making this a safe way to spread the dystrophin gene throughout the body,” added Duan.

“These dogs develop muscular dystrophy naturally in a similar manner as humans. It’s important to treat DMD early before the disease does a lot of damage as this therapy has the greatest impact at the early stages in life.”

Margaret Proctor Mulligan from the University of Missouri's School of Medicine said: “This discovery took our research team more than 10 years, but we believe we are on the cusp of having a treatment for the disease.”

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.